Lucence Diagnostics was founded by Dr. Tan Min-Han with the vision of solving the most complex diagnostic problems in medicine through the most innovative technology design possible. A world leader in medicine, Dr. Tan’s research has spanned diverse fields of clinical medicine, human genetics and medical data analytics to regularly rewrite orthodoxy. He is recognized internationally for the landmark discovery of the circulating tumor-endothelial cell cluster in the blood of cancer patients, thus overturning a fifty year scientific dogma. He and team members established the widely-cited lifetime cancer risks for a breast cancer syndrome involving germline PTEN mutation. Through his leadership of a 160,000 woman breast cancer screening study, he has developed improved breast cancer risk assessment approaches. Infused with the same DNA of restless and relentless innovation, Lucence is focused on delivering the highest quality services to patients and physicians to improve cancer care for all.
At Lucence, we are a team of exceptional individuals committed to a single cause: to fight cancer. As leaders from diverse fields including oncology, laboratory medicine, technology development and data science, we believe that making the most informed decision possible leads to better outcomes for our patients.